Introduction
Positron emission tomography has been widely used as a research tool in the investigation of the function of the normal brain and also in the evaluation of the reaction of the brain to various pathologic conditions, for example ischemia.
The main advantage of PET lies in its capacity to quantify, regionally, parameters such as cerebral blood flow, blood volume, oxygen consumption, glucose utilization and many others. Regional blood volume can be measured with ucoor C 5 0labelled hemoglobin. Regional blood flow can be measured with, for example, Hz 15 0 , or 15 0 -butanol. By measuring the 15 0 2 uptake in the brain oxygen extraction and oxygen consumption can be measured. There is normally a close correlation between the oxygen consumption, blood flow, glucose utilization, and neuronal activityi 8 • For activation studies the regional cerebral blood flow is usually measured using 15 0 -butanol. The very short half-life time of 15 0 (2 min) makes this tracer suitable for activation studies, and repeat examinations under different states of activation can be performed within a limited span of time, each study not taking more than 100 seconds or less. By fractioning the administration of the tracer into a higher multiplicity, improved statistics is also obtained 13 • The study protocol is important for activation studies. Care must be taken to eliminate as far as possible influence from unwanted sources. Unnecessary sound and light should be minimized.
The sequence of activation-rest should be randomized etc. Averaging is used in most activation studies 10 • Such averaging can be performed by multiple studies in the same individual (intrasubject). There is, however, a limit to how much radioactivity can be administered.
Averaging can also be performed by examining many individuals and then add them together after first having reformatted the images to a standard format (intersubject). This can be achieved by using a computerized brain atlas as suggested by Greitz et AP,4·n.
The atlas is first adapted to the individual brain by a series of linear and non linear transformations. The parameters describing the transformations are stored and are then applied "backwards" on the image data to transform the image to the standard atlas format (figures 2 and 3).
When all images from a group of individuals have the same format, the data can be averaged to form a standard brain from many individuals and with low noise.
One data set may then represent rest and others different states of activation. Subtraction can then be performed between these averaged images. Similarly, a standard normal brain can be constructed for each tracer of interest.
The PET study in an individual patient may then be more confidently analyzed by a procedure called individual-mean subtraction (Greitz ' principle) as demonstrated in figure 4 . High sensitivity and high resolution can be achieved with modern PET cameras. With 3D acquisition the signal to noise ration can be improved with about a factor ten5. 21 .
With modern PET technique activation studies may be performed by individual (intrasubject) averaging in much the same way as is now performed Figure 1 Markedly increased methionine accumulation in a large chordoma reflecting the increased blood volume, the defective bloodtumour barrier and the increased metabolic rate of methionine. with functional MR imaging. Detailed analyses of the function of the human brain under various conditions have now been performed in several thousand volunteers in many centres around the world.
Activation studies with PET is a well established and validated technique, which may be used to further validate the results of functional MR studies.
Among the advantages with PET are the higher 90 sensitivity and the capacity to disclose areas with deactivation. Among the disadvantages are the lower spatial resolution and the slightly lower time resolution.
The capacity for detailed analysis of various receptor ligands has been utilized mainly in psychiatric research. Receptor density in various systems and in various disorders have been extensively studied. This has been of value in the clinical trials of suggested substances for use in psychiatric patients, in the titration of optimal dosage, and in the design of new pharmaceuticals.
PET has also been used in the analysis of patients with epileptic seizures. These studies have been of clinical interest, and it has been suggested that patients with seizures constitute one of the rather few groups where PET may be of clinical significance, so far. FDG has been utilized for detection of interictal hypometabolic regions signifying epileptic foci. Benzodiazepine receptor ligands have also been used in this context 20 • It has been shown that the benzodiazepine receptor density is decreased in the focus regions in patients with partial epilepsy. Further, these zones were more pronounced, better delimited, and better correlated with ictal onset at EEG than the findings at PET with FDG.
PET has been of great clinical importance in the evaluation of brain tumours. PET in the study of brain tumours may be said to represent another as-pect of functional imaging: the metabolic characterization of pathologic tissue and a functional evaluation of response to treatment. It was early shown that most tumours showed a high accumulation of the essential amino acid methionine as compared to normal brain tissue 9 • Of particular interest was the fact that an increased accumulation of this tracer often was seen in tumours without a disruption of the blood-tumour barrier. It has further been shown that the methionine accumulation in tumours is a facilitated diffusion that can be decreased by the infusion of non labelled branched amino acids which compete for the transport mechanism.
The transport system over the barrier seems to be similar in tumours and in normal tissue, but with an often marked magnitude in tumours because an increased demand of the substance 1
Once the tracer has passed the blood-brain or blood-tumour barrier it is further transported to the intracellular space. In the cells the methionine molecule takes part in a variety of metabolic processes, an important one being to act as a methyl donor. If the labelling of methionine has been done in the methyl group, which is the easiest way, it is then lost. With the label in the carboxyl group it can be followed longer.
However, even if a large part of the injected methionine will be incorporated in proteins this is not a good tracer for measuring the protein synthesis rate, and kinetic models for the methionine dynamics should be interpreted with care, particularly with the label in the methyl group and particularly in grossly pathologic tissue.
In the clinical use of methionine it is, however, not necessary to apply kinetic models. It has been estimated that an increased accumulation of methionine is found in about 80% of all intracerebral tumours.
Tumours not exhibiting increased methionine accumulation are almost invariably astrocytomas grade II. Anecdotal exceptions have been described. Generally, there is an increasing accumulation of methionine with increasing malignancy grade.
However, oligodendrogliomas seem to be somewhat special in that they sometimes show a very high accumulation even in grade II cases.
The interpretation of increased methionine accumulation should be made with some caution. If there is a damage to the blood-brain barrier an increased accumulation of the tracer is to be expected even in non-tumourous tissue. Once the tracer is over the barrier, there is a considerably increased access to it for the cells and thereby an increased intracellular accumulation.
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Even in the absence of intracellular accumulation an increased uptake would be expected in a lesion with a barrier disruption since the tracer then would act like conventional contrast media for CT or MR use where enhancement is seen when contrast is accumulated in the extracellular space.
Thus, a radiation necrosis or an inflammatory lesion that exhibits contrast enhancement on CT or MR should be expected also to show increased accumulation of methionine, and a differentiation from tumour is then not possible.
However, increased methionine accumulation in the abcence of blood-tumour barrier disrupture should be regarded as indicating tumour until otherwise proven. It may be mentioned in this context that a negative biopsy is not proof of abscence of tumour. 18 F-Fluorodeoxyglucose (FDG) is the most widely used tracer for determination of the regional cerebral metabolic rate.
The kinetic model used for the quantitation is very well documented 12
• There is a coupling between the glucose utilization and the neuronal function, and FDG is therefore per se a valuable tracer for activation studies.
The long half-life time of 18 F (110 min), however, makes FDG impractical, if not impossible, to use for repeat studies for individual averaging. The model is partly based on assumptions that are valid for normal or near-normal brain tissue but probably not for grossly pathologic tissue.
The kinetic model may be applied to low-grade tumours with a preserved blood-tumour barrier, but caution is advised in more malignant tumours. Nevertheless, FDG has been extensively used for tumour studies 6 • In contrast to methionine, increased FDG uptake is generally not seen in low-grade intracerebral tumours, but only in anaplastic tumours and glioblastomas. Metastatic tumours usually exhibit increased FDG accumulation ( figure 4 ), but exceptions have been reported. Meningiomas arise outside the CNS and do not have a blood-tumour barrier.
The following general rules can be given: However, the FDG uptake is not always increased in these tumours, which on the other hand generally show an increased methionine accumulation (figures 1, 5, and 6).
Type of lesion
It has been claimed 7 that increased FDG accumulation is related to tumour aggressivity and tendency of recurrence.
Methionine can then be used to delineate tumours that are ill-defined at CT or MR. Methionine accumulation can also aid in directing biopsy to the metabolically most active tumour area, enhancing the chances of obtaining a representative sam-plel6.
An increased accumulation of methionine supports the diagnosis of tumour. Normal methionine accumulation does not, however, exclude an astrocytoma grade II.
A transition from reduced or normal methionine accumulation to increased uptake in a lesion would indicate malignant regression from a grade II to a grade Ill or IV tumour. Radiation necrosis, sometimes occurring after irradiation regardless of technique, poses diagnostic problems. At CT and MR it is in most cases not possible to differentiate between necrosis and tumour progression or malignant transformation.
Contrast enhancement is seen in a peripheral zone surrounding a central, non enhancing necrotic area, similarly in glioblastoma and necrosis. Methionine accumulation occurs in the peripheral zone due to the blood-tumour barrier breakdown in both lesions. FDG, however, is not accumulating in necrotic cells, but certainly in rapidly growing malignant cells.
PET studies with FDG have therefore become of great clinical value in the evaluation of these cases. This has become particularly interesting since the introduction of stereotactic radiosurgery for the treatment of intracranial metastases 15 • Most irradiated metastases respond rapidly to treatment. In some cases, however, the tumours are seen to grow, often after a period of regress.
An increased FDG accumulation in such a tumour would indicate growth of viable malignant cells, whereas a decreased accumulation indicates radiation reaction or necrosis 8 • It has been calculated that radiosurgery has a good effect in about 90% of treated intracerebral metastases. Of the remaining 10% about half have viable growing tumours and half have radiation re-actions14.
Stereotactic radiosurgery is sometimes contemplated on remaining tumours after incomplete surgical removal of skull base meningiomas. In these cases, surgical clips may degrade CT images and make delineation of the tumour rest uncertain (figure 5) .
PET is not inherent with the same kind of artefacts, and the methionine study more confidantly than CT shows the true extent of the remaining tu- mour. A dose planning kan then be performed based mainly on the PET examination ( figure 6) .
The injected doses typically are around 400 MBq for 11 C-methionine. 18 F-FDG, having a considerably longer half-life time, is usually injected in doses of about 150 MBq.
There are, of course, local variations in administered doses. In FDG studies the measurements are started 20-30 minutes after injection of the tracer to monitor mainly the radioactivity already trapped in the intracellular space. Methionine studies are usually started simultaneous with the injection to enable a dynamic analysis of the isotope distribution.
This difference in imagq acquisition, however, must be kept in mind when reviewing the images.
PET is of value as a complement to other methods in the clinical evaluation of brain tumour patients, but is not replacing standard methods as CT or MR.
The basic anatomic information is always obtained from CT and MR, and can only secondarily be obtained from PET.
The PET image contains only functional information. Due to the high resolution of present PET 94 systems a good anatomic orientation is nevertheless obtained. However, integration of PET with CT or, preferably, MR is recommended.
In this way the functional information from PET images may be better related to anatomy, and both domains be much better appreciated. Admittedly, PET is a highly specialized technique, and very expensive.
It can be argued that PET is a sophisticated research tool with limited clinical impact. Not only is an expensive positron camera required, but also a highly skilled radiochemical group for synthesis and labelling, and further access to a nearby cyclotron for isotope production.
The analysis of the resulting images should preferably include adjustment to the brain atlas and close comparison with other diagnostic examinations, such as CT and MR.
Not only are PET examinations expensive, but they also require a highly skilled staff, ready to devote considerable time for each study, resulting in a low patient through-put. However, centres with access to PET should be aware of the obvious advantages offered, particularly in the management of brain tumour patients.
